Republish from the special edition of Nextdeal (Issue 560)

Affidea Group is the largest provider of Primary Healthcare in Europe, with operations in 15 countries, more than 400 medical centers, and over 17,000 healthcare professionals. Every year, 20 million examinations are performed for 14 million patients. In Greece, Affidea has a 20-year track record of leadership, offering reliable and safe high-quality diagnostic services. Its centers are equipped with state-of-the-art medical technology, highly trained personnel, and are contracted with EOPYY, public funds, and private insurance companies.

Affidea is actively investing in the digital transformation of its diagnostic centers, aiming to create a new model of “smart” diagnostic services that place people at the center. By utilizing digital technologies and eliminating the use of paper, the company seeks to improve patient experience, enhance operational efficiency, and reduce its environmental footprint. In this context, it developed the “myAffidea” app, a digital tool for holistic health management, offering citizens easy, secure, and immediate access to their examination results and medical history.

At the same time, Affidea is strengthening its strategic presence in European health technology through its participation in the i2X project (Intelligent Implementations of the European Electronic Health Record Exchange Format). This is a key European initiative for the interoperability of medical data among EU member states, paving the way for the creation of a Unified European Health Data Space.

The integration with the National Health Record, further reinforced by the i2X project, enables citizens to consolidate all their health-related information in one place, enhancing transparency, safety, and personalized care. In this way, Affidea establishes itself as a key player in the field of digital health in Europe, accelerating the transition to a more interoperable, human-centered, and technologically supported healthcare system.

Affidea strategically invests in modern equipment to ensure that all patients benefit from the latest advancements in medical technology—delivering faster and more accurate imaging in a safe and patient-friendly environment. Its equipment is among the newest in Europe, capable of performing both standard and complex diagnostic tests that provide detailed insights into patients’ health status. Notably, Affidea is equipped with the most advanced MRI and CT scanners, 3D digital mammography systems, ultrasound imaging, and more—technology designed with patient comfort and safety in mind.

By implementing procedures focused on safeguarding patient safety and achieving the best possible medical outcomes, Affidea places people first. As part of this approach, it has introduced the Dose Excellence program, a pioneering initiative for optimizing radiation dosage during CT scans. As a result, Affidea centers are listed on the “EuroSafe Wall of Stars” among the best and safest in Europe in terms of radiation protection. In addition, the MRI Excellence program applies during magnetic resonance imaging, combining high diagnostic accuracy with time-efficient scanning procedures.

With a consistent investment strategy, Affidea is shaping the future of diagnostic medicine—where technology and human care coexist harmoniously to deliver the highest possible standard of healthcare.

Read below the article from the special edition of Nextdeal (Issue 560) in electronic format, page 84 (click bottom right to enlarge)